2 unknown, 1 completed. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Unknown 2, Completed 1 |
Follow CC-11050: new trials by email Literature Review of CC-11050 trials Research Report on CC-11050
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CC-11050 Trial in Nepalese Patients With Erythema Nodosum Leprosum CC-11050 - Erythema Nodosum Leprosum, Leprosy | Phase 2 | Unknown | The Leprosy Mission Nepal | 50 | 2018-01-07 | 2020-07-07 |
| TB Host Directed Therapy Everolimus 0.5 MG, Auranofin 6 MG, Vitamin D3 - Tuberculosis | Phase 2 | Unknown | The Aurum Institute NPC | 200 | 2016-11-01 | 2019-01-10 |
| To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus CC-11050, Placebo - Cutaneous Lupus Erythematosus | Phase 2 | Completed | Amgen | 48 | 2010-10-01 | 2020-06-23 |
Leprosy (1) · Lupus Erythematosus, Cutaneous (1) · Lupus Erythematosus, Discoid (1) · Tuberculosis (1)
Amgen (1) · The Aurum Institute NPC (1) · The Leprosy Mission Nepal (1)
Nepal (1) · South Africa (1) · United States (1)
Mahesh Shah, MD (1) · Robert S Wallis, MD,FIDSA (1)